Hos 139 børn med kongenitial hjertesygdom, som haved kardio- pulminærr bypass og fik palivizumab, og hvis serumprøver fandtes tilgængelige, låg middelkoncentrationen af palivizumab i serum på 100 µg/ ml før hjertebypass og sank til 40 µg/ ml efter bypass.
Among 139 children in the congenital heart disease study receiving palivizumab who had cardio-pulmonary bypass and for whom paired serum samples were available, the mean serum palivizumab concentration was approximately 100 μ g/ ml pre-cardiac bypass and declined to approximately 40 μ g/ ml after bypass.